A new breast cancer therapy significantly increases the chances of survival of sick women, according to a study. Treatment with an increase in the substance ribociclib leads to a survival rate of 70 percent after three and a half years, as US researchers announced on Saturday, citing an international clinical study. In subjects who received a placebo, the death rate was therefore 29 percent higher. The study involved 670 women under the age of 60 who had advanced breast cancer.
An active ingredient gets rid of the breast cancer
According to the study's lead author, Sara Hurvitz, the studies focused on the most common form of breast cancer associated with the hormone estrogen. This is generally treated with an anti-hormone therapy. In combination with the active ingredient ribociclib, however, significantly better results could be achieved, said Hurvitz. Ribociclib inhibits the activity of enzymes that influence the division of cancer cells. Baby warns his mother about breast cancer in 1846
Get real time update about this post categories directly on your device, subscribe now.